Kris Elverum

Kris Elverum is an experienced executive in the biopharmaceutical industry, currently serving as President and Chief Executive Officer of AIRNA, a company focused on RNA editing therapeutics since March 2023. Prior to this role, Kris held various leadership positions, including Member of the Board of Advisors at Navega Therapeutics and consultant for biopharma firms. Kris has also served as CEO at 4:59 NewCo and Rubius Therapeutics, where responsibilities included strategic development and transformation initiatives. Notably, Kris negotiated significant partnerships at Turnstone Biologics and held crucial roles at SQZ Biotech and Novartis, where leadership in cell and gene therapies was pivotal. Kris's career began at McKinsey & Company, and academic credentials include an M.B.A. and B.S. in Business with a minor in Chemistry from the University of Minnesota - Carlson School of Management.